IL160404A0 - Prostaglandin compositions and methods of treatment for male erectile dysfunction - Google Patents

Prostaglandin compositions and methods of treatment for male erectile dysfunction

Info

Publication number
IL160404A0
IL160404A0 IL16040402A IL16040402A IL160404A0 IL 160404 A0 IL160404 A0 IL 160404A0 IL 16040402 A IL16040402 A IL 16040402A IL 16040402 A IL16040402 A IL 16040402A IL 160404 A0 IL160404 A0 IL 160404A0
Authority
IL
Israel
Prior art keywords
aliphatic
composition
ester
erectile dysfunction
prostaglandin
Prior art date
Application number
IL16040402A
Other languages
English (en)
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of IL160404A0 publication Critical patent/IL160404A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16040402A 2001-09-06 2002-09-06 Prostaglandin compositions and methods of treatment for male erectile dysfunction IL160404A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/947,617 US6693135B2 (en) 2000-01-10 2001-09-06 Prostaglandin compositions and methods of treatment for male erectile dysfunction
PCT/US2002/028507 WO2003022310A1 (en) 2001-09-06 2002-09-06 Prostaglandin compositions and methods of treatment for male erectile dysfunction

Publications (1)

Publication Number Publication Date
IL160404A0 true IL160404A0 (en) 2004-07-25

Family

ID=25486427

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16040402A IL160404A0 (en) 2001-09-06 2002-09-06 Prostaglandin compositions and methods of treatment for male erectile dysfunction

Country Status (19)

Country Link
US (1) US6693135B2 (de)
EP (1) EP1423147B1 (de)
JP (1) JP4544859B2 (de)
KR (1) KR20040033024A (de)
CN (1) CN1551784A (de)
AT (1) ATE330635T1 (de)
AU (1) AU2002323650B2 (de)
BR (1) BR0212352A (de)
CA (1) CA2457895A1 (de)
DE (1) DE60212651D1 (de)
EA (1) EA009384B1 (de)
GE (1) GEP20063982B (de)
HU (1) HU229602B1 (de)
IL (1) IL160404A0 (de)
MX (1) MXPA04002133A (de)
NZ (1) NZ531806A (de)
UA (1) UA79759C2 (de)
WO (1) WO2003022310A1 (de)
ZA (1) ZA200401437B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) * 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
EA008720B1 (ru) * 1998-12-10 2007-06-29 Нексмед (Холдингс), Инк. Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
CN1774237A (zh) * 2003-03-21 2006-05-17 尼克美制药控股有限公司 前列腺素组合物及其促进血管生成的方法
KR101086147B1 (ko) 2003-03-21 2011-11-25 넥스메드 홀딩스 인코포레이티드 조루증 치료용 조성물 및 치료 방법
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060127483A1 (en) * 2004-12-10 2006-06-15 Alan Drizen Topical drug delivery system
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
CA2665081C (en) 2006-10-02 2015-12-01 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
EP2091914A4 (de) * 2006-11-08 2010-12-29 Chongxi Yu Transdermale verabreichungssysteme für peptide und verwandte verbindungen
CN107652212B (zh) 2007-01-15 2019-11-15 于崇曦 维生素a酸类和类维生素a酸化合物的前药
JP2010529101A (ja) * 2007-06-04 2010-08-26 テックフィールズ インコーポレイテッド 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用
CN108191846B (zh) 2008-12-04 2021-08-20 于崇曦 高穿透性组合物及其应用
EP2660247A3 (de) 2009-05-08 2014-09-03 Chongxi Yu Prodrug-Zusammensetzungen mit hoher Durchdringung aus Peptiden und Peptidverbindungen
CA2745320A1 (en) 2011-07-06 2013-01-06 Duoject Medical Systems Inc. Reconstitution device
CN104161720A (zh) * 2014-07-07 2014-11-26 中山尼克美制药有限公司 一种治疗勃起功能障碍的外用前列腺素e1乳膏及制备方法
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc エルゴリン化合物およびその使用
MX2017009406A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo isoergolina y usos de estos.
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
WO2022265537A1 (ru) * 2021-06-18 2022-12-22 Общество с ограниченной ответственностью "ИнертГаз Медикал" Способ лечения эректильной дисфункции

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
BE790840A (fr) 1971-11-01 1973-04-30 Upjohn Co Solutions de medicaments instables et leur preparation
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
CA2352552C (en) 1990-04-25 2008-12-02 Virgil A. Place Treatment of erectile dysfunction
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
JP3202777B2 (ja) 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
CZ278497A3 (cs) 1995-03-14 1998-04-15 Vivus, Incorporated Způsob a sestava zařízení k prevenci impotence
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6224573B1 (en) * 1999-01-15 2001-05-01 Nexmed Holdings, Inc. Medicament dispenser
US6102849A (en) 1999-04-03 2000-08-15 Hakac; John R. Non-surgical penile prosthesis
WO2001035998A1 (en) 1999-11-12 2001-05-25 Pharmaderm Laboratories, Ltd. Compositions for transdermal and transmucosal administration of therapeutic agents
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction

Also Published As

Publication number Publication date
CN1551784A (zh) 2004-12-01
EA200400398A1 (ru) 2004-08-26
GEP20063982B (en) 2006-12-11
ATE330635T1 (de) 2006-07-15
US20020045665A1 (en) 2002-04-18
CA2457895A1 (en) 2003-03-20
UA79759C2 (en) 2007-07-25
ZA200401437B (en) 2005-05-25
EP1423147A1 (de) 2004-06-02
JP2005504073A (ja) 2005-02-10
US6693135B2 (en) 2004-02-17
KR20040033024A (ko) 2004-04-17
WO2003022310A1 (en) 2003-03-20
MXPA04002133A (es) 2004-06-29
HUP0401816A3 (en) 2012-09-28
DE60212651D1 (de) 2006-08-03
EP1423147B1 (de) 2006-06-21
HUP0401816A2 (hu) 2004-12-28
NZ531806A (en) 2006-05-26
AU2002323650B2 (en) 2007-12-13
HU229602B1 (en) 2014-02-28
JP4544859B2 (ja) 2010-09-15
BR0212352A (pt) 2004-07-27
EA009384B1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
IL150306A0 (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction
HU229602B1 (en) Prostaglandin compositions and their use for preparation of medicaments sutable for treatment of male erectile dysfunction
ATE273714T1 (de) Topische zusammensetzungen zur prostaglandin e1 abgabe
MXPA05009816A (es) Composiciones y metodos para el tratamiento de la eyaculacion precoz.
TR200202308T2 (tr) Prostaglandin E1 içeren tropikal bileşimler
YU2503A (sh) Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
DE68910520D1 (de) Verfahren zur Verminderung von Hautirritationen bei Anwendung von durchdringungsverstärkenden Arzneimittelzusammensetzungen.
NO934355D0 (no) Proteinformulering omfattende veksthormon
EA199700213A1 (ru) Крем на водной основе для локального применения, способ его приготовления, способ лечения эректильной дисфункции у мужчин, способ лечения аноргазма у женщин, способ лечения микроваскулярных заболеваний и способ лечения ран или хирургических рассечений
ATE208183T1 (de) Deodorant- und antitranspirantpräparate
IL156549A0 (en) Method and composition for the treatment of diabetic neuropathy
BR9408023A (pt) Formulações de fenbendazol
EP1222919A3 (de) Zusammensetzungen enthaltend Glykoproteinematrix und Wirkstoff und Verfahren zur Herstellung desselben
CA2442479A1 (en) Topical compositions for prostaglandin e1 delivery
BG99197A (en) Means for the treatment of cataract and method for its preparation